Of interest, Vermeulen et al. (96) reported that a combined application of antagonists for TRPV1 and TRPA1 could reduce the VMR more effectively in TNBS-induced colitis, in comparison to targeting either TRPV1 or TRPA1 alone. This evidence concerns the gene TRPA1 and colitis.